Objectives: Teclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission). An expert consensus survey and meeting were conducted among European specialists in multiple myeloma treatment to evaluate current and future outpatient administration with teclistamab and talquetamab in clinical practice.
Methods: All experts completed a 17-question survey, participated in an individual follow-up call, and attended an online consensus meeting in September 2024.
Results: There was strong agreement that outpatient treatment with teclistamab and talquetamab is feasible, with implementation already seen in some centers. Factors identified as potential criteria to define patient eligibility include cognitive status, caregiver presence, and distance from the hospital. While outpatient administration is not yet widely adopted due to limited experience with bispecific antibodies, the expert panel expects up to 50% of patients receiving teclistamab and talquetamab could be treated in an outpatient setting within 3 years.
Conclusions: Sharing best practices, robust protocol development, and evidence from clinical trials and real-world experience will support the implementation of outpatient treatment with bispecific antibodies, which could relieve hospital resources and improve patients' treatment experience.
Keywords: Europe; antibodies; bispecific; consensus; hematology; multiple myeloma; outpatients; talquetamab; teclistamab.
© 2025 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.